Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants

Cytokine

Volumn 51, Issue 3, 2010, Pages 251-258

  Alonso Villaverde, Carlos ^a   Aragonès, Gerard ^a   Beltrán Debón, Raúl ^a   Fernández Sender, Laura ^a   Rull, Anna ^a   Rodríguez Sanabria, Fernando ^a   Marsillach, Judit ^a   Pardo Reche, Pedro ^a   Camps, Jordi ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Genotype; Haplotype; HIV; Inflammation; Insulin resistance

Indexed keywords

ADENINE; CD4 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; CYTOSINE; EFAVIRENZ; GLUCOSE; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; THYMINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CCL2 PROTEIN, HUMAN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FEMORAL ARTERY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENE LINKAGE DISEQUILIBRIUM; GENETICS; METABOLISM;

ADULT; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; FEMALE; GENETIC VARIATION; HAPLOTYPES; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MODELS, BIOLOGICAL;

EID: 77955272471     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.05.008     Document Type: Article

References (44)

1. Gonzalez E., Rovin B.H., Sen L., Cooke G., Dhanda R., Mummidi S., et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002, 99:13795-13800.
2. Carrington M., Dean M., Martin M.P., O'Brien S.J. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999, 8:1939-1945.
3. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997, 277:959-965.
4. Arenzana-Seisdedos F., Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin Immunol 2006, 18:387-403.
5. Samson M., Labbe O., Mollereau C., Vassart G., Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996, 35:3362-3367.
6. Ioannidis J.P., Rosenberg P.S., Goedert J.J., Ashton L.J., Benfield T.L., Buchbinder S.P., et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001, 135:782-795.
7. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
8. Rull A., Escola-Gil J.C., Julve J., Rotllan N., Calpe-Berdiel L., Coll B., et al. Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. Exp Mol Pathol 2007, 83:361-366.
9. Bielinski S.J., Pankow J.S., Miller M.B., Hopkins P.N., Eckfeldt J.H., Hixson J., et al. Circulating MCP-1 levels shows linkage to chemokine receptor gene cluster on chromosome 3: the NHLBI family heart study follow-up examination. Genes Immun 2007, 8:684-690.
10. Vilades C., Broch M., Plana M., Domingo P., Alonso-Villaverde C., Pedrol E., et al. Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2 -2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr 2007, 44:132-138.
11. Coll B., Alonso-Villaverde C., Parra S., Rabassa A., Martorell L., Joven J., et al. Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy. HIV Med 2006, 7:356-360.
12. Alonso-Villaverde C., Coll B., Parra S., Montero M., Calvo N., Tous M., et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004, 110:2204-2209.
13. Coll B., van Wijk J.P., Parra S., Castro Cabezas M., Hoepelman I.M., Alonso-Villaverde C., et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 2006, 544:104-110.
14. Coll B., Alonso-Villaverde C., Joven J. Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker?. Clin Chim Acta 2007, 383:21-29.
15. Teferedegne B., Green M.R., Guo Z., Boss J.M. Mechanism of action of a distal NF-kappaB-dependent enhancer. Mol Cell Biol 2006, 26:5759-5770.
16. Spooner C.J., Guo X., Johnson P.F., Schwartz R.C. Differential roles of C/EBP beta regulatory domains in specifying MCP-1 and IL-6 transcription. Mol Immunol 2007, 44:1384-1392.
17. Sekine O., Nishio Y., Egawa K., Nakamura T., Maegawa H., Kashiwagi A. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem 2002, 277:36631-36639.
18. Kodama K., Nishio Y., Sekine O., Sato Y., Egawa K., Maegawa H., et al. Bidirectional regulation of monocyte chemoattractant protein-1 gene at distinct sites of its promoter by nitric oxide in vascular smooth muscle cells. Am J Physiol Cell Physiol 2005, 289:C582-C590.
19. Sutton B.S., Langefeld C.D., Campbell J.K., Haffner S.M., Norris J.M., Scherzinger A.L., et al. Genetic mapping of a 17q chromosomal region linked to obesity phenotypes in the IRAS family study. Int J Obes (Lond) 2006, 30:1433-1441.
20. Ferré N., Camps J., Fernández-Ballart J., Arija V., Murphy M.M., Ceruelo S., et al. Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in general population. Clin Chem 2003, 49:1491-1497.
21. Simó J.M., Castellano I., Ferré N., Joven J., Camps J. Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clin Chem 1998, 44:1233-1241.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. Martínez E., Mocroft A., García-Viejo M.A., Pérez-Cuevas J.B., Blanco J.L., Mallolas J., et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
25. McDermott D.H., Yang Q., Kathiresan S., Cupples L.A., Massaro J.M., Keaney J.F., et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005, 112:1113-1120.
26. Tobler A.R., Short S., Andersen M.R., Paner T.M., Briggs J.C., Lambert S.M., et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J Biomol Tech 2005, 16:398-406.
27. Schnabel R.B., Baumert J., Barbalic M., Dupuis J., Ellinor P.T., Durda P., et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2009, 10.1182/blood-2009-05-221382.
28. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100:7265-7270.
29. van Leth F., Phanuphak P., Stroes E., Gazzard B., Cahn P., Raffi F., et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.
30. Alonso-Villaverde C., Coll B., Gomez F., Parra S., Camps J., Joven J., et al. The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS 2005, 19:341-342.
31. Freedman D.S., Kahn H.S., Mei Z., Grummer-Strawn L.M., Dietz W.H., Srinivasan S.R., et al. Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr 2007, 86:33-40.
32. Turner S.T., Peyser P.A., Kardia S.L., Bielak L.F., Sheedy P.F., Boerwinkle E., et al. Genomic loci with pleiotropic effects on coronary artery calcification. Atherosclerosis 2006, 185:340-346.
33. Asanuma Y., Chung C.P., Oeser A., Shintani A., Stanley E., Raggi P., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006, 33:539-545.
34. Sedlmeier E.M., Grallert H., Huth C., Lowel H., Herder C., Strassburger K., et al. Gene variants of monocyte chemoattractant protein 1 and components of metabolic syndrome in KORA S4, Augsburg. Eur J Endocrinol 2007, 156:377-385.
35. Ng M.C., So W.Y., Lam V.K., Cockram C.S., Bell G.I., Cox N.J., et al. Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 2004, 53:2676-2683.
36. Simeoni E., Hoffmann M.M., Winkelmann B.R., Ruiz J., Fleury S., Boehm B.O., et al. Association between the A -2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 2004, 47:1574-1580.
37. Noor M.A. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV/AIDS Rep 2007, 4:126-134.
38. Maruyama-Furuta N., Yano Y., Gabazza E.C., Suematsu M., Matsumoto K., Akatsuka H., et al. Monocyte chemoattractant protein-1 promoter -2518 polymorphism is associated with post-challenge insulin and glucose levels in non-diabetic Japanese subjects. Diabetes Res Clin Pract 2007, 78:208-210.
39. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999, 259:344-348.
40. Hughes A.L., Yeager M. Coevolution of the mammalian chemokines and their receptors. Immunogenetics 1999, 49:115-124.
41. Goldstein D.B., Weale M.E. Population genomics: linkage disequilibrium holds the key. Curr Biol 2001, 11:R576-R579.
42. Vitart V., Carothers A.D., Hayward C., Teague P., Hastie N.D., Campbell H., et al. Increased level of linkage disequilibrium in rural compared with urban communities: a factor to consider in association-study design. Am J Hum Genet 2005, 76:763-772.
43. Murphy M.M., Vilella E., Ceruelo S., Figuera L., Sanchez M., Camps J., et al. The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 2002, 48:372-375.
44. Clark V.J., Dean M. Characterisation of SNP haplotype structure in chemokine and chemokine receptor genes using CEPH pedigrees and statistical estimation. Hum Genomics 2004, 1:195-207.